Education

Cornell University, B.A., 1985, Genetics
University of Connecticut School of Medicine, M.D., 1989, Medicine
Harbor-UCLA Medical Center, 1992, Internal Medicine
University of California, San Francisco, 1996, Hematology and Oncology

Honors & Awards

  • 1984
    Cornell Tradition Fellow Award
  • 1989
    LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT
  • 2003
    Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA

Selected Publications

  1. Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, Martin TG, Wolf J, Wong SW, Wiita AP, Shah N. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study. Br J Haematol. 2023 Feb 27.  View on PubMed
  2. Kennedy VE, Natsuhara K, Shah ND, Arora S, Wolf J, Martin TG, Aras MA, Chung A, Wong SW. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Curr Probl Cancer. 2023 Feb 14; 47(3):100953.  View on PubMed
  3. Martin TG, Capra M, Mohty M, Suzuki K, Quach H, Cavo M, Moreau P, Dimopoulos M, Yong K, Tekle C, Foster MC, Barnes Y, Risse ML, Mikhael J. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. Transplant Cell Ther. 2022 Nov 11.  View on PubMed
  4. Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchausp? M, Casca F, Mac? S, Van de Velde H, Suzuki K. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica. 2022 10 01; 107(10):2485-2491.  View on PubMed
  5. Martin T, Jackson CC, Pacaud L, Madduri D, Jagannath S. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jan; 23(1):22-27.  View on PubMed
  6. Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 12; 36(12):2917-2921.  View on PubMed
  7. Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022 Nov; 199(4):520-528.  View on PubMed
  8. Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat Biotechnol. 2022 Aug 25.  View on PubMed
  9. Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosi?ol L, Yagci M, Cavo M, Risse ML, Asset G, Mac? S, van de Velde H, Yong K. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov; 109(5):504-512.  View on PubMed
  10. Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C, Garg M, Quach H, Sia H, George A, Konstantinova T, Risse ML, Asset G, Mac? S, van de Velde H, Moreau P. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Adv. 2022 08 09; 6(15):4506-4515.  View on PubMed
  11. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD, Mullins RD, Eyquem J, Wells JA, Wiita AP. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022 07 15; 13(1):4121.  View on PubMed
  12. Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosi?ol L, Yagci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec; 40(5):1020-1029.  View on PubMed
  13. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9.  View on PubMed
  14. Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf J, Martin TG, Shah N, Wong SW. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021 12 14; 5(23):5344-5348.  View on PubMed
  15. Dinh AR, Wong SW, Martin TG, Wolf JL, Webber AB. Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. Clin Transplant. 2022 03; 36(3):e14541.  View on PubMed
  16. Tam AH, Jung Y, Young R, Huang CY, Wolf J, Shah N, Wong SW, Martin TG, Lo M. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. J Oncol Pharm Pract. 2022 Dec; 28(8):1819-1825.  View on PubMed
  17. Banerjee R, Lo M, Martin TG. Isatuximab, carfilzomib�and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. Future Oncol. 2021 Dec; 17(35):4849-4860.  View on PubMed
  18. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449.  View on PubMed
  19. Sun H, Martin TG, Marra J, Kong D, Keats J, Mac? S, Chiron M, Wolf JL, Venstrom JM, Rajalingam R. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma. J Immunother Cancer. 2021 07; 9(7).  View on PubMed
  20. Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Mac? S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 05 12; 11(5):89.  View on PubMed

Go to UCSF Profiles, powered by CTSI